Sedana Medical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Sedana Medical şirketinin toplam hissedar öz sermayesi SEK950.0M ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK998.2M ve SEK48.2M dir.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 226.39m
Eşitlik	SEK 949.99m
Toplam yükümlülükler	SEK 48.24m
Toplam varlıklar	SEK 998.24m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 7D2A 'nin kısa vadeli varlıkları ( SEK308.8M ) kısa vadeli yükümlülüklerini ( SEK44.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: 7D2A şirketinin kısa vadeli varlıkları ( SEK308.8M ) uzun vadeli yükümlülüklerini ( SEK3.5M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 7D2A borçsuzdur.

Borcun Azaltılması: 7D2A un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 7D2A şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: 7D2A tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Sedana Medical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Supply Chain & Manufacturing Director recently bought €13k worth of stock

New minor risk - Profitability

No longer forecast to breakeven

Third quarter 2024 earnings released: kr0.22 loss per share (vs kr0.069 loss in 3Q 2023)

Sedana Medical AB (publ) to Report Q1, 2025 Results on May 06, 2025

Second quarter 2024 earnings released: kr0.17 loss per share (vs kr0.014 profit in 2Q 2023)

Sedana Medical AB (publ) (OM:SEDANA) agreed to acquire Innovatif Cekal Sdn. Bhd. for SEK 35 million.

Less than half of directors are independent

Sedana Medical AB (publ) Completes Patient Recruitment for its Clinical Program in the US

First quarter 2024 earnings released: EPS: kr0.21 (vs kr0.16 loss in 1Q 2023)

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Ola Magnusson and Eva Walde Decline Re-Election as Board Members of Sedana Medical AB (publ)

Full year 2023 earnings released: kr0.60 loss per share (vs kr0.74 loss in FY 2022)

Full year 2023 earnings released: kr0.60 loss per share (vs kr0.74 loss in FY 2022)

Forecast to breakeven in 2026

Sedana Medical AB (publ) Files Submission for Paediatric Indication

Sedana Medical Secures Data Exclusivity and Market Protection for Sedaconda (isoflurane) Until 2031

Sedana Medical AB (Publ) Announces the Main Results from the Paediatric Isocomfort Study

Chief Medical Officer recently bought €76k worth of stock

Sedana Medical AB (publ), Annual General Meeting, May 22, 2024

Third quarter 2023 earnings released: kr0.07 loss per share (vs kr0.075 loss in 3Q 2022)

Sedana Medical AB (publ) Announces Completion of Enrollment

Sedana Medical AB (publ) Announces Medicines and Healthcare Products Regulatory Agency Grants Marketing Authorization for Sedaconda (Isoflurane) in United Kingdom

Chief Financial Officer recently bought €154k worth of stock

No longer forecast to breakeven

New minor risk - Profitability

Second quarter 2023 earnings released: EPS: kr0.01 (vs kr0.11 loss in 2Q 2022)

New minor risk - Profitability

Sedana Medical AB (publ) Informs About Adjusted US Submission Plan Following FDA Interaction

Sedana Medical AB (Publ) Announces Thomas Eklund Decline Re-Election

Full year 2022 earnings released: kr0.74 loss per share (vs kr0.63 loss in FY 2021)

Full year 2022 earnings released: kr0.74 loss per share (vs kr0.63 loss in FY 2021)

Sedana Medical AB (publ) Receives Market Approval for Sedaconda in Italy

Sedana Medical AB (publ) to Report Fiscal Year 2022 Final Results on Apr 03, 2023

Sedana Medical AB (publ) Completes Patient Recruitment for Pediatric IsoCOMFORT Study

Sedana Medical Receives FDA Fast Track Designation in the United States

Sedana Medical Receives Positive Opinion from Ema's Pediatric Committee on Reduced Pediatric Study Design

No longer forecast to breakeven

No longer forecast to breakeven

Third quarter 2022 earnings released: kr0.08 loss per share (vs kr0.16 loss in 3Q 2021)

Sedana Medical AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Second quarter 2022 earnings released: kr0.11 loss per share (vs kr0.19 loss in 2Q 2021)

Sedana Medical AB (publ) Approves Board Changes

Forecast breakeven date pushed back to 2024

First quarter 2022 earnings released: kr0.19 loss per share (vs kr0.097 loss in 1Q 2021)

Sedana Medical Announces Enrolment of First Patient in US Clinical Program

Full year 2021 earnings released: kr0.63 loss per share (vs kr0.30 loss in FY 2020)

Forecast breakeven date pushed back to 2023

Forecast breakeven date pushed back to 2023

Forecast breakeven date moved forward to 2022

Forecast breakeven date pushed back to 2023

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Sedana Medical AB (publ) to Report Q1, 2022 Results on Apr 28, 2022

Sedana Medical AB (publ), Annual General Meeting, May 11, 2022

Sedana Medical AB (publ) to Report Q4, 2021 Results on Feb 17, 2022

Forecast to breakeven in 2022

Sedana Medical Receives Investigational New Drug Approval for US Trials

Sedana Medical AB Applies for Market Approval in Italy

Independent Director recently sold €97k worth of stock

Sedana Medical AB (publ) Submits IND for U.S Clinical Trials

Third quarter 2021 earnings released: kr0.17 loss per share (vs kr0.15 loss in 3Q 2020)

Independent Director recently sold €289k worth of stock

Forecast to breakeven in 2022

Second quarter 2021 earnings released: kr0.19 loss per share (vs kr0.039 loss in 2Q 2020)

Sedana Medical Receives Approval in France

Independent Director has left the company

First quarter 2021 earnings released: kr0.39 loss per share (vs kr0.075 profit in 1Q 2020)

Full year 2020 earnings released: kr1.19 loss per share (vs kr0.78 loss in FY 2019)

Full year 2020 earnings released: kr1.19 loss per share (vs kr0.78 loss in FY 2019)

Revenue beats expectations

Sedana Medical AB (publ) Announces Resignation of Its CEO Christer Ahlberg

Sedana Medical AB (publ) Announces Inclusion of First Patient in Pediatric Study IsoCOMFORT

Sedana Medical AB (publ) Submits Application for Market Approval in UK

New 90-day high: €36.55

New 90-day high: €35.75